Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 18, Issue 14, 2017, Pages 1433-1438

  Ohta, Akio ^a   Kato, Hiroyuki ^a   Ishii, Satoshi ^a   Sasaki, Yosuke ^a   Nakamura, Yuta ^a   Nakagawa, Tomoko ^a   Nagai, Yoshio ^a   Tanaka, Yasushi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

appendicular skeletal mass index; fat index; intrahepatic lipid content; intrahepatic visceral fat volume; Ipragliflozin; subcutaneous fat volume; type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; LIPID; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; BODY FAT; BONE MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC PATIENT; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRAPERITONEAL FAT; JAPANESE (PEOPLE); LIPID LIVER LEVEL; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; DIAGNOSTIC IMAGING; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INTRAABDOMINAL FAT; LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; X-RAY COMPUTED TOMOGRAPHY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; INTRA-ABDOMINAL FAT; LIPIDS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85027337209     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2017.1363888     Document Type: Article

References (23)

1. Després JP, Lemieux I., Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887.
2. Yki-Järvinen H., Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–910.
3. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013;309:2250–2261.
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;NEJMoa1611925. [Epub].
6. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
7. Takase T, Nakamura A, Miyoshi H, et al. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J. 2017;64:363–367.
8. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
9. Jojima T, Tomotsune T, Iijima T, et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016;8:45.
10. Honda Y, Imajo K, Kato T, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One. 2016;11:e0146337.
11. Komiya C, Tsuchiya K, Shiba K, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in Type 2 diabetic patients irrespective of body weight reduction. PLoS One. 2016;11:e0151511.
12. Tsukiyama H, Nagai Y, Matsubara F, et al. Proposed cut-off values of the waist circumference for metabolic syndrome based on visceral fat volume in a Japanese population. J Diabetes Investig. 2016;7:587–593.
13. Matsubara F, Nagai Y, Tsukiyama H, et al. Proposed cut-off value of the intrahepatic lipid content for metabolically normal persons assessed by proton magnetic resonance spectroscopy in a Japanese population. Diabetes Res Clin Pract. 2016;119:75–82.
14. Vendrell J, El Bekay R, Peral B, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 2011;152:4072–4079.
15. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513–519.
16. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
17. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–657.
18. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48:434–441.
19. Hawley SA, Ford RJ, Smith BK, et al. The Na+/Glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65:2784–2794.
20. Sada Y, Katabami T, Asai S, et al. Intrahepatic lipid content is linked to insulin resistance in obese subjects. Obes Res Clin Pract. 2011;5:e79–e156.
21. Tosato M, Marzetti E, Cesari M, et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. Aging Clin Exp Res. 2017;29:19–27.
22. Heymsfield SB, Adamek M, Gonzalez MC, et al. Assessing skeletal muscle mass: historical overview and state of the art. J Cachexia Sarcopenia Muscle. 2014;5:9–18.
23. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–1735.